ACHIEVING INDEPENDENCE: PROVIDING PATIENTS WITH THE TOOLS TO MANAGE THEIR CARE

PRESENTING AUTHOR: **Elizabeth "Betty Ann" Paradis**
Sudbury and North-Eastern Ontario Hemophilia Program
Health Sciences North, Sudbury
Ontario, Canada

CO-AUTHOR: **Laura Hilbig**
Bayer HealthCare LLC

INTRODUCTION AND OBJECTIVES:

Treatment of hemophilia A often requires infusion of factor VIII up to three times a week. Learning to self-infuse is an important, but sometimes difficult, step for patients in becoming independent and adhering to their treatment regimen. The KidK Self-Infusion Program (KidK) is designed to help people with hemophilia learn to more independently manage their condition.

MATERIALS AND METHODS:

Until they can learn to self-infuse, children with hemophilia receive infusions at home from a parent or in the HTC by the hemophilia nurse. Hemophilia Solutions by Bayer created KidK to help these young people achieve greater responsibility over their treatment by practicing self-infusion in a safe and secure environment. The KidK kit also features a training program to help train doctors, nurses and caregivers to teach children how to self-infuse.

The program offers an educational booklet, featuring a fictional character named KidK who is facing the same challenge (learning to self-infuse) as well as a training kit to help them master this skill. Central to this is the BayCuff™ device, which contains an artificial vein for practicing. Piercing the artificial vein with a needle produces a "flashback," similar to what a person would see if they were infusing into their own vein. This positive visual cue helps them gain confidence in their technique before performing it on their own veins.

KidK A Self Infusion Program
Launched 2008

SELF-INFUSION TRAINING KIT BASIK TRAINING
Launched 2013

50K+
Kits Distributed

46
Countries Worldwide

25+
Languages Available

RESULTS:

The program is offered in Kogenate® FS/ KOGENATE® Bayer markets. Since the program's launch in 2008, more than 50,000 of the kits have been distributed in nearly 50 countries and the written material provided in over 25 languages, attesting to the value of this educational tool and kit.

Older members of the community also can use the device. In 2013, Bayer launched a new training program, BASIK Training (Bayer Adult Self-Infusion Kit). Its purpose is to help teach caregivers or teenagers and adults whose treatment regimens may not have led them to learn to self-infuse.

CONCLUSION:

The KidK Self-Infusion Program helps people with hemophilia understand and become comfortable with an important step in their treatment.

KOGENATE® FS [octocog alfa (bhk) - recombinant Factor VIII]

INDICATIONS: Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital Factor VIII deficiency). May be used in patients with Factor VIII inhibitors who continue to respond to infused Factor VIII. Not indicated in von Willebrand's disease. **DOSAGE AND ADMINISTRATION:** Clinical studies have demonstrated a mean rise of about 2% in Factor VIII activity for each unit of KOGENATE FS transfused per kg body weight. The following formulae can be used to determine the appropriate dose required for a given response: Required IU = body weight (kg) x desired Factor VIII rise (% of normal) x 0.5; or the response to be expected from a given dose: Expected Factor VIII rise (% of normal) = 2 x administered IU ÷ body weight (kg). Dosage and duration of therapy must be individualised according to patient's needs (weight, severity of haemostatic function disorder, site and extent of bleeding, titre of inhibitors, and desired Factor VIII level). **CONTRAINDICATIONS:** Known intolerance or allergic reactions to constituents of KOGENATE FS. PRECAUTIONS: Hypersensitivity to KOGENATE FS, plasma-derived Factor VIII, or biological preparations with traces of proteins; if allergic or anaphylactic reactions occur, injection/infusion should be stopped immediately. Monitoring to ensure adequate Factor VIII levels have been reached and are maintained. Immunogenicity; monitoring for development of antibodies to Factor VIII; cardiovascular risk factors; catheter-related infections; use in pregnancy and lactation. Interactions: Besides known interactions of Factor VIII with other coagulation proteins, no other interactions with other drugs have been established. Analgesics (e.g. acetylsalicylic acid, phenylbutazone, indomethacin) should not be given to haemophiliacs. **ADVERSE EFFECTS:** Factor VIII inhibition, infusion site reactions, rash, pruritis, urticaria, pyrexia, anaphylactic reaction, hypersensitivity, dysgeusia. Others: See full Product Information.

Before prescribing, please review full Product Information available on request from Bayer Australia Ltd (ABN 22 000 138 714), 875 Pacific Highway, Pymble, NSW 2073.

®Registered trademark of Bayer AG, Germany

G.SM.HEM.04.2014.0200 exp-15-April-2016

Hemophilia Solutions
Never Losing Sight of the Human Factor

WFH2014 208--P-T
Self-Infusion and Home Treatment
Elizabeth Betty Ann Paradis
DOI: 10.3252/pso.eu.WFH2014.2014
Poster presented at: WFH 2014 World Congress

PosterSessionOnline.com